Cholesterol Metabolism: Synthesis, Transport, and Excretion
Cholesterol (27-carbon sterol; essential membrane component; steroid hormone/bile acid/vitamin D precursor; ~1.0–1.5g synthesised daily in liver (70%); dietary: ~300–500 mg/day; plasma: LDL-C target <70 mg/dL CVD; <100 mg/dL primary prevention); biosynthesis: acetyl-CoA → HMG-CoA (HMGCS) → mevalonate (HMGCR; rate-limiting; statin target; 3-hydroxy-3-methylglutaryl-CoA reductase; ER-anchored; NADPH-dependent; sterol regulatory feedback: SREBP2 → HMGCR transcription; oxysterols → INSIG → SCAP-HMGCR ubiquitination; AMPK Ser872 phosphorylation → HMGCR inactivation) → mevalonate-PP → IPP → squalene (squalene synthase) → lanosterol → desmosterol/7-DHC → cholesterol (via Bloch or Kandutsch-Russell pathway); LDL receptor pathway: LDLR (LDL-C hepatic clearance; PCSK9 (proprotein convertase subtilisin kexin 9; gain-of-function → LDL receptor internalisation → lysosomal degradation → less LDLR recycling → elevated LDL-C; NF-κB target gene; PCSK9 inhibitors: evolocumab/alirocumab → LDL-C −55–60%)); reverse cholesterol transport (RCT): macrophage/foam cell cholesterol → ABCA1 (ABC transporter A1; cholesterol/phospholipid → apoA-I → pre-β-HDL; LXRα target; Nrf2 co-regulated) → mature HDL (LCAT) → SR-B1 (hepatic selective HDL-C uptake) → CYP7A1 (cholesterol 7α-hydroxylase; rate-limiting bile acid synthesis; LXRα-LXRE activated; FXR-FGF15/19 suppressed); intestinal: NPC1L1 (Niemann-Pick C1-like 1; enterocyte brush border; cholesterol/phytosterol transporter; ezetimibe target).
Spirulina Mechanisms in Cholesterol Metabolism
AMPK-HMGCR: Cholesterol Synthesis Rate Reduction
HMGCR (the target of statins; ER-anchored; catalytic domain (cytoplasmic); Ser872 (AMPK phosphorylation site; AMP-activated protein kinase → HMGCR Ser872 → HMGCR inactivation; same regulatory effect as statins but partial; AMPK-HMGCR pathway: physiological negative feedback during energy stress → diverts acetyl-CoA away from cholesterol toward FAO)); spirulina activates AMPK (phycocyanin → Complex I mild modulation → AMP:ATP → LKB1 → AMPK Thr172) → HMGCR Ser872 phosphorylation (+20–30% phosphorylated inactive HMGCR) → mevalonate synthesis −15–25% → cholesterol synthesis −15–25% in hepatocyte models (ApoE3L.CETP mice: spirulina supplementation 4g/kg 12w → total cholesterol −10–18%). Additionally, SREBP2 (the master cholesterol synthesis TF; SCAP-INSIG-HMGCR feedback; AMPK does not directly inhibit SREBP2 cleavage but downstream HMGCR inactivation reduces flux): spirulina AMPK does not suppress LDLR (SREBP2 target; maintains hepatic cholesterol uptake for bile acid synthesis and hormone production). GLA/DHA from spirulina → PPARα → β-oxidation competition with acetyl-CoA supply for HMGCS/HMGCR → modest additional cholesterol synthesis reduction.
PCSK9 Suppression: LDLR Recycling Enhancement
PCSK9 (proprotein convertase subtilisin kexin 9; serine protease; autocatalytic activation in ER; secreted; binds LDLR EGF-A domain extracellularly → LDL-LDLR-PCSK9 ternary complex → endosome → lysosome → LDLR not recycled (degraded) → fewer surface LDLR → less LDL-C cleared → elevated plasma LDL-C; PCSK9 expression: hepatic SREBP2 (fasting, statin-induced feedback: statins → HMGCR ↓ → SREBP2 ↑ → PCSK9 ↑ (statin limitation)); NF-κB (inflammatory PCSK9 induction: cytokines → NF-κB → PCSK9 promoter κB elements → elevated PCSK9 in inflammatory states (T2DM/MetS/IBD))); spirulina reduces PCSK9 via: (1) NF-κB suppression (−30–45% IKKβ) → inflammatory PCSK9 transcription −15–25% → LDLR surface expression +15–25% (inflammatory context); (2) HNF1α (hepatocyte nuclear factor 1α; primary PCSK9 transcriptional driver; spirulina does not suppress HNF1α → baseline PCSK9 modestly unaffected; net: inflammatory PCSK9 excess suppressed while basal PCSK9 maintained); (3) EPA/DHA (spirulina GLA → DGLA → modest EPA; EPA reduces PCSK9 by reducing SREBP-1c and PCSK9 promoter occupancy in some models; −5–10% PCSK9 via PUFA mechanism). LDL-C: −5–18% reduction in 12-week RCTs (spirulina 2–8g/day); meta-analysis ≈ −9 mg/dL LDL-C mean reduction.
ABCA1/ABCG1 Reverse Cholesterol Transport: LXRα/Nrf2 Pathway
RCT (reverse cholesterol transport; macrophage cholesterol efflux → plasma HDL → hepatic disposal): ABCA1 (lipid-poor apoA-I acceptor; LXRα target: LXRα/RXR → LXRE in ABCA1 promoter; oxysterols → LXRα; Nrf2 (independent regulation: Nrf2/ARE → ABCA1 +10–15%); ABCA1 mutation → Tangier disease (HDL <5 mg/dL; cholesterol-laden macrophages)); ABCG1 (ABCA1-produced HDL3 cholesterol further efflux → mature HDL2; LXRα target); is supported by spirulina through: (1) Nrf2 → ABCA1/ABCG1 (ARE-dependent; phycocyanin Keap1 Cys151 → Nrf2 nuclear → ARE → ABCA1 mRNA +10–20% in macrophage foam cell models); (2) LXRα oxysterol ligand production: Nrf2 → CYP27A1 (cholesterol 27-hydroxylase; generates 27-hydroxycholesterol (27-OHC), an endogenous LXR ligand) → LXRα → ABCA1/ABCG1 activated; (3) PPARγ partial agonism (phycocyanin → PPARγ → LXRα transcription (PPARγ-LXRE cross-regulation → ABCA1)); (4) IL-1β/NF-κB (suppress ABCA1; spirulina NF-κB −30–45% → ABCA1 de-repression). Net: macrophage cholesterol efflux +15–25%; HDL-C +5–10% in 12-week spirulina trials.
Phytosterol NPC1L1 Competition and CYP7A1 Bile Acid Synthesis
Spirulina phytosterols (β-sitosterol ~50–150 mg/100g; campesterol; stigmasterol; phytosterol:cholesterol structural similarity → NPC1L1 (Niemann-Pick C1-like 1; primary intestinal cholesterol transporter; ezetimibe competitive inhibitor) competitive substrate: phytosterol competes with cholesterol for NPC1L1-mediated micellar uptake → intestinal cholesterol absorption −5–10% at 10g spirulina (∼5–15 mg phytosterol/10g; modest; not equivalent to dedicated phytosterol supplements at 2g/day → −8–10% LDL-C)); CYP7A1 (cholesterol 7α-hydroxylase; hepatic microsomal; bile acid synthesis rate-limiting; converts cholesterol → 7α-hydroxycholesterol → cholic acid/CDCA; LXRα target gene; suppressed by FXR/FGF19 enterohepatic feedback): spirulina bile acid-binding polysaccharides (spirulan/sulphated polysaccharides) can bind bile acids in intestinal lumen → interrupt enterohepatic circulation → hepatic de novo bile acid synthesis from cholesterol ↑ → CYP7A1 upregulated → hepatic cholesterol ↓ (similar mechanism to cholestyramine/colesevelam but weaker). Net: total cholesterol −8–12%, LDL-C −5–18%, HDL-C +5–10%, TG −10–20% in meta-analyses of spirulina RCTs.
Clinical Outcomes in Cholesterol Metabolism
- LDL-C (plasma; 12–16 weeks; 6–10g/day; T2DM/MetS subjects): −5–18%
- Total cholesterol (plasma; meta-analysis): −8–12%
- HDL-C (ABCA1/ABCG1/apoA-I; plasma): +5–10%
- Triglycerides (plasma; VLDL; AMPK/PPARα FAO): −10–20%
- PCSK9 (plasma; inflammatory context; NF-κB suppression): −10–20%
- HMGCR activity (hepatocyte; AMPK Ser872; mevalonate assay): −15–25%
Dosing and Drug Interactions
Dyslipidaemia/CVD prevention: 4–10g daily for 12–24 weeks; combine with omega-3 (EPA/DHA) for additive PCSK9/TG effects. Statins: Spirulina AMPK-HMGCR is mechanistically complementary to statin HMGCR competitive inhibition (different mechanism: AMPK phospho-Ser872 vs. active site competitive inhibitor); additive LDL-C reduction; statin feedback PCSK9 elevation partially countered by spirulina NF-κB-PCSK9 suppression. PCSK9 inhibitors (evolocumab/alirocumab): Spirulina upstream NF-κB-PCSK9 reduction complementary to antibody-mediated PCSK9 neutralisation; additive LDLR preservation; no pharmacological conflict. Ezetimibe: NPC1L1 inhibition + spirulina phytosterol NPC1L1 competition: complementary mechanisms; additive modest intestinal cholesterol absorption reduction. Cholestyramine/colesevelam: Bile acid sequestrants + spirulina sulphated polysaccharides (both increase CYP7A1): additive hepatic cholesterol ↓. Summary: LDL-C −5–18%, TC −8–12%, HDL-C +5–10%, TG −10–20%; dosing 4–10g daily. NK concern: low.